Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Xiamen Kingdomway Group Company (002626.SZ)
CNY15.01
+0.59 (+4.09%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 299 Yangguang West Road
Xiamen, CN
Xiamen, CN
CEO
Bin Jiang
Website
kingdomway.com
IPO
2011-10-28
ISIN CNE1000018X4
Description
Xiamen Kingdomway Group Company operates as a global producer and distributor of a variety of nutritional and health-focused goods. The company's offerings encompass a selection of fundamental raw ingredients, notably coenzyme Q10, Vitamin A, Vitamin D3, DHA derived from microalgae, and plant-based ARA. Furthermore, it manufactures ready-to-use dietary supplements and specialized sports nutrition products. Originally established in 1997, the firm was previously recognized as Xiamen Jindawei Vitamin Co., Ltd., and maintains its principal offices in Xiamen, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY15.01
+0.59 (+4.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
5M
Beta
0.46
Float Shares
494.81M
Free Float %
81.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.74% | -5.00% | -4.04% | -22.42% | -19.67% | -22.93% | -16.31% | -21.46% | -67.26% | +4.83% | +107.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.01
DCF (Unlevered)
12.69
-15.4%
DCF (Levered)
11.20
-25.4%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
3.22
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
4 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+3.9% Q1'26: -1.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-1.8% Q1'26: -45.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.7% Q1'26: -12.4% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+13.0% ★ Q1'26: +12.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.2% ★ Q1'26: +7.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+4.4% Q1'26: -2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.22× ★ Q1'26: 4.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.20B
est: 1.20B (0.0%)
|
1.66B
est: 1.20B (+38.1%)
|
2.08B
est: 1.65B (+26.3%)
|
2.87B
est: 1.87B (+53.4%)
|
3.19B
est: 3.20B (-0.1%)
|
3.50B
est: 3.79B (-7.4%)
|
3.62B
est: 3.91B (-7.4%)
|
4.03B
est.
|
3.01B
est: 3.31B (-8.9%)
|
3.10B
est: 3.31B (-6.1%)
|
3.24B
est: 3.75B (-13.6%)
|
3.37B
est: 3.55B (-5.1%)
|
3.95B
3.95B – 3.95B
+11.3% YoY
|
4.57B
4.57B – 4.57B
+15.6% YoY
|
5.21B
5.21B – 5.21B
+14.1% YoY
|
| EBITDA |
243.28M
est: 292.63M (-16.9%)
|
481.26M
est: 292.63M (+64.5%)
|
670.01M
est: 401.15M (+67.0%)
|
971.06M
est: 455.17M (+113.3%)
|
801.61M
est: 776.69M (+3.2%)
|
1.30B
est: 920.08M (+40.8%)
|
1.10B
est: 949.50M (+16.3%)
|
978.91M
est.
|
514.69M
est: 803.40M (-35.9%)
|
539.44M
est: 803.40M (-32.9%)
|
663.08M
est: 785.03M (-15.5%)
|
647.12M
est: 743.14M (-12.9%)
|
827.27M
827.27M – 827.27M
+11.3% YoY
|
956.43M
956.43M – 956.43M
+15.6% YoY
|
1.09B
1.09B – 1.09B
+14.1% YoY
|
| EBIT |
171.66M
est: 237.93M (-27.9%)
|
393.47M
est: 237.93M (+65.4%)
|
586.79M
est: 326.17M (+79.9%)
|
873.03M
est: 370.09M (+135.9%)
|
681.43M
est: 631.52M (+7.9%)
|
1.18B
est: 748.11M (+58.2%)
|
968.50M
est: 772.03M (+25.4%)
|
795.94M
est.
|
350.69M
est: 653.24M (-46.3%)
|
374.90M
est: 653.24M (-42.6%)
|
501.00M
est: 592.12M (-15.4%)
|
437.80M
est: 560.52M (-21.9%)
|
623.98M
623.98M – 623.98M
+11.3% YoY
|
721.40M
721.40M – 721.40M
+15.6% YoY
|
822.77M
822.77M – 822.77M
+14.1% YoY
|
| Net Income |
112.57M
est: 121.99M (-7.7%)
|
299.77M
est: 121.99M (+145.7%)
|
474.05M
est: 280.57M (+69.0%)
|
687.25M
est: 323.27M (+112.6%)
|
450.71M
est: 433.05M (+4.1%)
|
959.21M
est: 1.27B (-24.4%)
|
788.86M
est: 1.45B (-45.7%)
|
1.19B
est.
|
257.40M
|
276.71M
|
341.99M
est: 363.33M (-5.9%)
|
339.91M
est: 471.69M (-27.9%)
|
535.44M
535.44M – 535.44M
+13.5% YoY
|
635.30M
635.30M – 635.30M
+18.7% YoY
|
790.40M
790.40M – 790.40M
+24.4% YoY
|
| SGA |
288.39M
est: 227.84M (+26.6%)
|
297.72M
est: 227.84M (+30.7%)
|
310.14M
est: 312.33M (-0.7%)
|
418.13M
est: 354.39M (+18.0%)
|
539.60M
est: 604.72M (-10.8%)
|
524.07M
est: 716.37M (-26.8%)
|
568.58M
est: 739.27M (-23.1%)
|
762.17M
est.
|
620.28M
est: 625.52M (-0.8%)
|
704.97M
est: 625.52M (+12.7%)
|
668.09M
est: 674.44M (-0.9%)
|
346.48M
est: 638.45M (-45.7%)
|
710.73M
710.73M – 710.73M
+11.3% YoY
|
821.69M
821.69M – 821.69M
+15.6% YoY
|
937.16M
937.16M – 937.16M
+14.1% YoY
|
| EPS |
0.20
est: 0.20 (+0.0%)
|
0.51
est: 0.20 (+155.0%)
|
0.77
est: 0.46 (+67.4%)
|
1.11
est: 0.53 (+109.4%)
|
0.73
est: 0.71 (+2.8%)
|
1.57
est: 2.08 (-24.5%)
|
1.29
est: 2.38 (-45.8%)
|
1.95
est.
|
0.42
|
0.45
|
0.56
est: 0.57 (-1.8%)
|
0.56
est: 0.74 (-24.3%)
|
0.84
0.84 – 0.84
+13.5% YoY
|
1.00
1.00 – 1.00
+18.7% YoY
|
1.24
1.24 – 1.24
+24.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
184.45M
OE per share TTM
0.31
Owner's Yield
2.04%
Maintenance CapEx ratio
343.30%
Maint CapEx / Avg PPE
44.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 22 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 71.8K | 0.65% |
| 2 | iShares Emerging Markets Equity Factor ETF EMGF | 0.01% | 179.7K | 0.26% |
| 3 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 34.9K | 0.49% |
| 4 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 617.7K | 0.07% |
| 5 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 335.7K | 0.06% |
| 6 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 176.6K | 0.39% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 6.9K | 0.44% |
| 8 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 11.6K | 0.48% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 26.1K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.29M | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
206.2K
Shares Outstanding
609.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bin Jiang | Chairman & GM | — | male |
| Chen Jia Liang | Executive Deputy GM & Non-Independent Director | — | male |
| Hang Hong | Chief Financial Officer, Deputy GM & Non-Independent Director | — | male |
| Hong Yun Huang | Accounting Supervisor | — | — |
| Zhan Guanghuang | Deputy General Manager | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002626.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
